Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical firm engaged in the discovery, development, and marketing of human medicines. The company serves patients worldwide across a wide range of therapeutic areas, including diabetes, oncology, immunology, neuroscience, infectious disease, and men’s and women’s health.

Key Therapeutic Areas and Products:

• Diabetes:

  • Basaglar, Humalog (U-100, U-200, Mix 75/25, Mix 50/50), Humulin (R, N, 70/30, U-500)

  • Insulin lispro-based formulations

  • Trulicity, Jardiance, and Trajenta for type 2 diabetes

• Oncology:

  • Alimta (NSCLC, pleural mesothelioma)

  • Cyramza (gastric, GEJ, lung, colorectal, liver cancers)

  • Erbitux (colorectal, head and neck cancers)

  • Retevmo (NSCLC, medullary and other thyroid cancers)

  • Tyvyt (Hodgkin’s lymphoma, NSCLC)

  • Verzenio (HR+, HER2- metastatic and early breast cancer)

• Immunology:

  • Olumiant (rheumatoid arthritis)

  • Taltz (plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis)

• Neuroscience & Pain Management:

  • Cymbalta (depression, anxiety, fibromyalgia, neuropathic and chronic pain)

  • Emgality (migraine prevention, episodic cluster headache)

  • Zyprexa (schizophrenia, bipolar I disorder)

• Infectious Diseases and Others:

  • Bamlanivimab and etesevimab, and Bebtelovimab (COVID-19)

  • Cialis (erectile dysfunction, benign prostatic hyperplasia)

  • Forteo (osteoporosis)

Eli Lilly has strategic partnerships with:
Incyte, Boehringer Ingelheim, AbCellera Biologics, Junshi Biosciences, Regor Therapeutics, Lycia Therapeutics, Kumquat Biosciences, Entos Pharmaceuticals, and Foghorn Therapeutics.

These collaborations support the company’s research in oncology, immunology, diabetes, neuroscience and rare diseases.

Founded in 1876, Eli Lilly is headquartered in Indianapolis, Indiana.